

Filippo Ballerini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1894779/publications.pdf>

Version: 2024-02-01

39
papers

955
citations

567281

15
h-index

434195

31
g-index

39
all docs

39
docs citations

39
times ranked

1611
citing authors

#	ARTICLE	IF	CITATIONS
1	Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 117-122.	2.0	324
2	Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. <i>Leukemia and Lymphoma</i> , 2002, 43, 2301-2307.	1.3	90
3	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab217.	0.9	64
4	Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5001-5007.	1.6	46
5	Thalidomide in agnogenic and secondary myelofibrosis. <i>British Journal of Haematology</i> , 2001, 115, 313-315.	2.5	43
6	WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 1961-1969.	1.3	37
7	Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 1606-1611.	0.8	36
8	Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. <i>European Journal of Haematology</i> , 2004, 72, 113-120.	2.2	28
9	Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. <i>Annals of Hematology</i> , 2004, 83, 696-703.	1.8	26
10	Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e348-e351.	3.5	26
11	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013, 31, 179-182.	1.7	20
12	Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. <i>Clinical Drug Investigation</i> , 2011, 31, 745-758.	2.2	18
13	High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. <i>American Journal of Hematology</i> , 2016, 91, 755-762.	4.1	18
14	A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of NPM1-mutated acute myeloid leukemia patients with worse prognosis. <i>American Journal of Hematology</i> , 2018, 93, E33-E35.	4.1	16
15	Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. <i>Annals of Hematology</i> , 2014, 93, 2011-2018.	1.8	15
16	IL-1-releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors. <i>Haematologica</i> , 2015, 100, e42-e45.	3.5	14
17	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	13
18	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. <i>British Journal of Haematology</i> , 2019, 184, 457-460.	2.5	13

#	ARTICLE	IF	CITATIONS
19	Performance of serum (1,3)- β -glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. <i>Mycoses</i> , 2018, 61, 650-655.	4.0	11
20	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. <i>Cancers</i> , 2021, 13, 34.	3.7	10
21	Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. <i>Oncology Reports</i> , 2005, 14, 933-40.	2.6	10
22	The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. <i>Annals of Hematology</i> , 2009, 88, 855-861.	1.8	9
23	Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. <i>Leukemia and Lymphoma</i> , 2012, 53, 2214-2217.	1.3	9
24	Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with <i>NPM1</i> mutation: from definition of molecular relapse to MRD-driven salvage approach. <i>British Journal of Haematology</i> , 2019, 186, e223-e225.	2.5	9
25	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 86, 106223.	0.8	7
26	Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 84-90.	1.3	7
27	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 107, 573-582.	2.2	7
28	Hodgkin's lymphoma: post- autologous transplantation consolidation therapy. <i>Acta Biomedica</i> , 2020, 91, 23-29.	0.3	5
29	Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 1348-1351.	1.3	4
30	Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1695-1701.	1.3	4
31	De novo AML patients with favourable "intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". <i>Annals of Hematology</i> , 2013, 92, 1309-1318.	1.8	3
32	Good tolerability of high dose colistin-based therapy in patients with haematological malignancies. <i>Infection</i> , 2017, 45, 505-511.	4.7	3
33	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038.	3.7	3
34	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. <i>Blood</i> , 2021, 138, 134-134.	1.4	3
35	Feasibility of Single-Port Laparoscopic Lymph Node Biopsy for Intra-Abdominal Lymphoma: A Case Series. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2021, 31, 458-461.	1.0	2
36	Role of Liposomal Daunorubicin, Fludarabine and Cytarabine (FLAD) in the Salvage Therapy of Adult Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 2527-2530.	1.3	1

#	ARTICLE	IF	CITATIONS
37	A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. Blood, 2015, 126, 1375-1375.	1.4	1
38	Prompt detection of Lâ€asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. Hematological Oncology, 2018, 36, 498-499.	1.7	0
39	SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia. Blood, 2016, 128, 5222-5222.	1.4	0